Bardia Nourbakhsh, MD
Neurology · Baltimore, MDNPI 1760709976
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,500 of the $2,003 with a category attached, or 74.9%. Alkermes, Inc. accounts for 74.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $1,590 and has fallen 77.3% since, to $361 in 2025.
Across 9 payments — averaging $222.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- Genentech USA, Inc.$359
- Genentech, Inc.$91
- Amgen$53
Across 14 payments — averaging $77,829 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.1M
- F. Hoffmann-la Roche AG$2K
- Modernatx, Inc.$55
What the payments were for
- Consulting fees$1,50075%
- Food & beverage$50325%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 1 | $1,500 |
| Genentech USA, Inc. | 4 | $359 |
| Genentech, Inc. | 3 | $91 |
| Amgen | 1 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ocrevus Zunovo$106
How this compares
$2,003 in reported general payments places this provider in the 55th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 38 | $331,664 |
| TecfideraDimethyl Fumarate | 21 | $180,129 |
| BetaseronInterferon Beta-1b | 13 | $120,496 |
| ProvigilModafinil | 13 | $57,715 |
| Dalfampridine ErDalfampridine | 104 | $33,923 |
| EliquisApixaban | 39 | $14,691 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,870 |
| Baclofen | 51 | $2,193 |
| Albuterol Sulfate | 12 | $1,289 |
| Tizanidine Hcl | 14 | $1,255 |
| Modafinil | 26 | $1,249 |
| Divalproex Sodium | 74 | $1,147 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 25 | $1,099 |
| Pregabalin | 19 | $1,082 |
| Memantine Hcl | 56 | $1,069 |
Paid to pharmacies, not to this prescriber.
Other neurology in Baltimore
- Michael PolydefkisBaltimore$371K
- Shiv SaidhaBaltimore$298K
- Santiago Mazuera MesiaBaltimore$258K
- Thomas CrawfordBaltimore$215K
- Scott NewsomeBaltimore$203K
- Perry ForemanBaltimore$194K
- Samuel MillerBaltimore$179K
- Ted DawsonBaltimore$170K
- Charlene GamaldoBaltimore$131K
- Kathryn WagnerBaltimore$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.